platelet aggregation factor | 77249-80-0

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 甘油磷脂
• 英文名称: platelet aggregation factor
• 英文别名: 2-O-acetyl-3-O-hexadecyl-sn-glycero(1)phosphocholine；3-O-Hexadecyl-2-O-acetyl-sn-glycero-1-phosphocholin；3-O-hexadecyl-2-O-acetyl-sn-glycero-1-phosphocholine；3-O-hexadecyl-2-acetoyl-sn-glycero-1-phosphocholine；1-hexadecyl-2-acetyl-sn-glycero-3-phosphocholine；Enantio-platelet-activating factor C16；[(2S)-2-acetyloxy-3-hexadecoxypropyl] 2-(trimethylazaniumyl)ethyl phosphate
• CAS: 77249-80-0
• 化学式: C₂₆H₅₄NO₇P
• 分子量: 523.691
• InChiKey: HVAUUPRFYPCOCA-SANMLTNESA-N

物化性质

• 熔点：
  247 °C

计算性质

• 辛醇/水分配系数(LogP)：
  6.5
• 重原子数：
  35
• 可旋转键数：
  26
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.96
• 拓扑面积：
  94.1
• 氢给体数：
  0
• 氢受体数：
  7

反应信息

• 作为产物：
  描述：

  1-十六烷醇 在 4-二甲氨基吡啶 、 三氟甲磺酸三甲基硅酯 、 (S,S)-(salen)Co(III)-OTs 、 boron trifluoride acetonitrile 、 三乙胺 、 N,N-二异丙基乙胺 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 反应 104.33h， 生成 platelet aggregation factor
  参考文献：
  名称：

  Catalytic synthesis of enantiopure mixed diacylglycerols – synthesis of a major M. tuberculosis phospholipid and platelet activating factor

  摘要：

  一种高效催化的一锅法合成TBDMS保护的二酰基甘油已被开发出来，从手性纯甘油酸环丙烷开始，随后无迁移的脱保护步骤产生立体化学和区域化学纯的二酰基甘油。这种新颖的策略已应用于合成主要的结核分枝杆菌磷脂、其脱甲基类似物和血小板活化因子。

  DOI：

  10.1039/c3ob41483c

文献信息

• An enantioselective synthesis of platelet-activating factors, their enantiomers, and their analogues from D- and L-tartaric acids.
  作者：MASAJI OHNO、KAGARI FUJITA、HISAO NAKAI、SUSUMU KOBAYASHI、KEIZO INOUE、SHOSHICHI NOJIMA

  DOI：10.1248/cpb.33.572

  日期：——

  Acetyl glyceryl ether phosphorylcholines (platelet-activating factors ; PAFs), their enantiomers, and their analogues were efficiently synthesized in a stereochemically unambiguous manner starting from D-and L-tartaric acids as chiral synthons. The enantiomer of C16-PAF (S-comfiguration) showed far less activity than the natural PAF (R-configuration), and the N-methylpiperidine and N-methylpyrrolidine analogues were found to possess much higher activity than natural C16-PAF.

  乙酰甘油醚磷脂酰胆碱（血小板激活因子；PAFs）、其对映体及其类似物以立体化学明确的方式有效合成，起始于D-和L-酒石酸作为手性合成前体。C16-PAF的对映体（S-构型）显示出远低于天然PAF（R-构型）的活性，而N-甲基哌啶和N-甲基吡咯烷的类似物则显示出比天然C16-PAF更高的活性。
• Drug delivery system for use in the treatment of vascular and vessel-related pathologies
  申请人：Academisch Medisch Centrum

  公开号：EP2210590A1

  公开（公告）日：2010-07-28

  The present invention relates to a drug delivery system for use in the treatment of vascular and vessel-related pathologies, comprising a drug delivery platform that comprises at least one compound capable of exerting an effect on the formation and/or maintenance of a thrombus in the vessel to be treated. The platform is preferably formed by liposomes that are sterically stabilized by grafting of poly(ethylene glycol) onto the liposome surface. The liposomes may further comprise photosensitizers and targeting molecules. The liposomes may be thermosensitive. The compound is suitably tranexamic acid. The drug delivery system is preferably used for the treatment of port wine stains.

  本发明涉及一种用于治疗血管和血管相关病症的给药系统，该系统包括一个给药平台，该平台包含至少一种能够对待治疗血管中血栓的形成和/或维持产生影响的化合物。该平台最好由脂质体形成，脂质体表面接枝聚乙二醇使其立体稳定。脂质体可进一步包含光敏剂和靶向分子。脂质体可具有热敏性。化合物宜为氨甲环酸。该给药系统最好用于治疗波特酒渍。
• Liposomal formulation of nonglycosidic ceramides and uses thereof
  申请人：LUDWIG INSTITUTE FOR CANCER RESEARCH LTD.

  公开号：US10039715B2

  公开（公告）日：2018-08-07

  The invention provides liposomes containing nonglycosidic ceramides within their bilayers, and compositions thereof. These liposomes activate murine iNKT cells and induce dendritic cell (DC) maturation, both in vitro and in vivo at an efficacy that is comparable to their corresponding soluble nonglycosidic ceramides. Also provided are methods for treating diseases using the liposomes and compositions of the invention.

  本发明提供了在其双层内含有非糖苷类神经酰胺的脂质体及其组合物。这些脂质体可在体外和体内激活小鼠 iNKT 细胞并诱导树突状细胞（DC）成熟，其功效与相应的可溶性非糖苷神经酰胺相当。此外，还提供了使用本发明脂质体和组合物治疗疾病的方法。
• Protein particles for therapeutic and diagnostic use
  申请人：——

  公开号：US20020142046A1

  公开（公告）日：2002-10-03

  Albumin particles in the nanometer and micrometer size range in an aqueous suspension are rendered stable against resolubilization without the aid of a cross-linking agent and witout denaturation, by the incorporation of a stabilizing agent in the particle composition. Stabilizing agents disclosed include reducing agents, oxdizing agents, hydrogen-accepting molecules, high molecular weight polymers, and sulfur-containing ring compounds. Also disclosed are fibrinogen-coated particles, cross-linked or non-cross-linked, and their use as co-aggregants with platelets and with themselves for purposes of shortening bleeding time and enhancing the effect of thrombin.

  通过在颗粒组合物中加入稳定剂，可使水悬浮液中纳米和微米大小的白蛋白颗粒在不借助交联剂和不发生变性的情况下稳定地防止溶解。已公开的稳定剂包括还原剂、氧化剂、氢接受分子、高分子量聚合物和含硫环化合物。此外，还公开了交联或非交联的纤维蛋白原涂层微粒，以及它们作为与血小板和自身的共聚物的用途，以达到缩短出血时间和增强凝血酶效果的目的。
• System and method for in vitro bleeding time testing
  申请人：——

  公开号：US20040143174A1

  公开（公告）日：2004-07-22

  The invention includes an in vitro bleeding time device having an opening through a sheet of material across an outlet. At least a portion the sheet of material contains a coating which includes collagen type I, fibrinogen, fibronectin, and von Willebrand factor. The invention includes a blood coagulation analysis system which has a device with an internal chamber for receiving a blood sample through an inlet. A sheet of material spans a flowpath through a single device outlet. A controller regulates pressure and or flow rate within the device. The invention includes a method for analyzing blood coagulation. Blood provided into a device chamber flows out through an opening through a sheet of material which spans the device outlet. A controller is utilized to control pressure and/or flow rate within the device by controlling the flow rate into the device during formation of a clot blockage of the opening.

  本发明包括一种体外出血时间装置，它有一个穿过材料片的开口，横跨出口。材料片的至少一部分含有涂层，该涂层包括 I 型胶原、纤维蛋白原、纤连蛋白和冯-维勒布兰德因子。本发明包括一种血液凝固分析系统，该系统有一个带有内腔的装置，用于通过入口接收血液样本。材料薄片横跨流道，通过单个设备出口。控制器可调节装置内的压力和流速。本发明包括一种分析血液凝固的方法。进入设备腔室的血液从一个开口流出，流经横跨设备出口的材料片。利用控制器控制装置内的压力和/或流速，方法是在开口处形成血块堵塞时控制进入装置的流速。